{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:13:40Z","timestamp":1790633620757,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:00:00Z","timestamp":1445472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00198-015-3335-3","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T10:47:59Z","timestamp":1445597279000},"page":"853-859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015"],"prefix":"10.1007","volume":"27","author":[{"given":"A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Compston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"3335_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20137","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. JBMR 30:3\u201323","journal-title":"JBMR"},{"key":"3335_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060\u20134","journal-title":"Am J Med"},{"issue":"10","key":"3335_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 72(10):1938\u201356","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415\u201323","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3899\/jrheum.100221","volume":"38","author":"AA Khan","year":"2011","unstructured":"Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396\u2013402","journal-title":"J Rheumatol"},{"key":"3335_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","volume":"72","author":"M Ulmner","year":"2014","unstructured":"Ulmner M, Jarnbring F, Torring O (2014) Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 72:76\u201382","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR8","first-page":"691","volume":"35","author":"M Etminan","year":"2008","unstructured":"Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691\u20135","journal-title":"J Rheumatol"},{"key":"3335_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/pds.3292","volume":"21","author":"P Tennis","year":"2012","unstructured":"Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810\u20137","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3335_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","volume":"139","author":"JT Grbic","year":"2008","unstructured":"Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC et al (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32\u201340","journal-title":"J Am Dent Assoc"},{"key":"3335_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","volume":"18","author":"JP Devogelaer","year":"2007","unstructured":"Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211\u20138","journal-title":"Osteoporos Int"},{"key":"3335_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694\u2013701","journal-title":"J Bone Miner Res"},{"key":"3335_CR13","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Tedlbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Edocrinol Metab 97:3161\u20139","journal-title":"J Clin Edocrinol Metab"},{"key":"3335_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u201365","journal-title":"N Engl J Med"},{"key":"3335_CR15","first-page":"4489","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4489\u201392","journal-title":"J Clin Endocrinol Metab"},{"key":"3335_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","volume":"64","author":"Z Al","year":"2006","unstructured":"Al Z (2006) Bisphosphonates are associated with increased risk of jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917\u201323","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","volume":"19","author":"M Pazianas","year":"2008","unstructured":"Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19:773\u20139","journal-title":"Osteoporos Int"},{"key":"3335_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","volume":"141","author":"JT Grbic","year":"2010","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141:1365\u201370","journal-title":"J Am Dent Assoc"},{"key":"3335_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20137","journal-title":"Ann Oncol"},{"issue":"16","key":"3335_CR20","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combineb analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u201392","journal-title":"Eur J Cancer"},{"key":"3335_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrendo.2010.195","volume":"7","author":"CA Migliorati","year":"2011","unstructured":"Migliorati CA, Epstein JB, Abt E, Berenson JR (2011) Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 7:34\u201342","journal-title":"Nat Rev Endocrinol"},{"key":"3335_CR22","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","volume":"29","author":"M Pazianas","year":"2007","unstructured":"Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548\u201358","journal-title":"Clin Ther"},{"key":"3335_CR23","first-page":"3","volume":"30","author":"A Hokugo","year":"2010","unstructured":"Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW et al (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"3335_CR24","first-page":"358","volume":"7","author":"MR Allen","year":"2007","unstructured":"Allen MR (2007) Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 7:358\u201360","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"3335_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000151371","volume":"189","author":"MR Allen","year":"2009","unstructured":"Allen MR (2009) Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 189:289\u201394","journal-title":"Cells Tissues Organs"},{"key":"3335_CR26","doi-asserted-by":"crossref","unstructured":"Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. 2015;1-6","DOI":"10.1177\/0022034515572021"},{"key":"3335_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/14740338.7.4.491","volume":"7","author":"SJ Wimalawansa","year":"2008","unstructured":"Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491\u2013512","journal-title":"Expert Opin Drug Saf"},{"key":"3335_CR28","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rates. Cancer Res 62:6538\u201344","journal-title":"Cancer Res"},{"key":"3335_CR29","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893\u20137","journal-title":"Clin Cancer Res"},{"key":"3335_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/jir.2005.25.144","volume":"25","author":"B Vincenzi","year":"2005","unstructured":"Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144\u201351","journal-title":"J Interferon Cytokine Res"},{"key":"3335_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","volume":"44","author":"A Brunello","year":"2009","unstructured":"Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with subitinib in a patient with metastatic renal cell carcinoma. Bone 44:173\u20135","journal-title":"Bone"},{"key":"3335_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181\u20138","journal-title":"Breast Cancer Res Treat"},{"key":"3335_CR33","first-page":"579","volume":"6","author":"BC English","year":"2010","unstructured":"English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL et al (2010) A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 6:579\u201383","journal-title":"Ther Clin Risk Manag"},{"key":"3335_CR34","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","volume":"112","author":"ME Sarasquete","year":"2008","unstructured":"Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chill\u00f3n MC, Balanzategui A et al (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709\u201312","journal-title":"Blood"},{"key":"3335_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","volume":"40","author":"J Katz","year":"2011","unstructured":"Katz J, Gong Y, Salmasina D, Hou W, Burkley B, Ferreira P et al (2011) Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 40:605\u201311","journal-title":"Int J Oral Maxillofac Surg"},{"key":"3335_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","volume":"17","author":"P Nicoletti","year":"2012","unstructured":"Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A (2012) Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17:279\u201387","journal-title":"Oncologist"},{"key":"3335_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00784-009-0300-6","volume":"14","author":"S Hoefert","year":"2010","unstructured":"Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 14:271\u201384","journal-title":"Clin Oral Investig"},{"key":"3335_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1834-7819.2008.00078.x","volume":"53","author":"R Kunchur","year":"2008","unstructured":"Kunchur R, Goss AN (2008) The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 53:354\u20137","journal-title":"Aust Dent J"},{"key":"3335_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.joms.2009.07.068","volume":"68","author":"G Lodi","year":"2010","unstructured":"Lodi G, Sardella A, Salis A, Demarosi F, Rarozzi M, Carrassi A (2010) Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 68:107\u201310","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR40","first-page":"b147","volume":"77","author":"R Bonacina","year":"2011","unstructured":"Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147","journal-title":"J Can Dent Assoc"},{"key":"3335_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243\u201351","journal-title":"J Am Dent Assoc"},{"key":"3335_CR42","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tripleo.2011.07.004","volume":"112","author":"F Moretti","year":"2011","unstructured":"Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C (2011) A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:777\u201382","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"3335_CR43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.joms.2010.10.055","volume":"69","author":"S Ferlito","year":"2009","unstructured":"Ferlito S, Puzzo S, Liardo C (2009) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69:e1\u20134","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR44","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","volume":"363","author":"JD Bashutski","year":"2010","unstructured":"Bashutski JD, Eber RM, Kinney JS et al (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363:2396\u2013405","journal-title":"N Engl J Med"},{"key":"3335_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","volume":"112","author":"G Subramanian","year":"2011","unstructured":"Subramanian G, Cohen HV, Quek SY (2011) A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:744\u201353","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"3335_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","volume":"65","author":"RP Harper","year":"2007","unstructured":"Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573\u201380","journal-title":"J Oral Maxillofac Surg"},{"key":"3335_CR47","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.081176","volume":"36","author":"AN Lau","year":"2009","unstructured":"Lau AN, Adachi JD (2009) Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rjeumatol 36:1835\u20137","journal-title":"J Rjeumatol"},{"key":"3335_CR48","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMc1002684","volume":"363","author":"A Cheung","year":"2010","unstructured":"Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473\u20134","journal-title":"N Engl J Med"},{"key":"3335_CR49","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hed.21380","volume":"33","author":"JJ Lee","year":"2011","unstructured":"Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH (2011) Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 33:1366\u201371","journal-title":"Head Neck"},{"key":"3335_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1754-4505.2009.00128.x","volume":"30","author":"P Narongroeknawin","year":"2010","unstructured":"Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR (2010) Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dent 30:77\u201382","journal-title":"Spec Care Dent"},{"key":"3335_CR51","first-page":"547","volume":"32","author":"J Iwamoto","year":"2012","unstructured":"Iwamoto J, Yago K, Sato Y, Matsumoto H (2012) Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis. Clin Drug Investig 32:547\u201353","journal-title":"Clin Drug Investig"},{"key":"3335_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","volume":"111","author":"F Wilde","year":"2011","unstructured":"Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A et al (2011) The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:153\u201363","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"3335_CR53","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","volume":"137","author":"T Mucke","year":"2011","unstructured":"Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA et al (2011) Outcome of treatment and parameters influencing recurrence in patients with bisphosphonates-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 137:907\u201313","journal-title":"J Cancer Res Clin Oncol"},{"key":"3335_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","volume":"11","author":"N Ngamphaiboon","year":"2011","unstructured":"Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL (2011) Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab. Clin Breast Cancer 11:252\u20137","journal-title":"Clin Breast Cancer"},{"key":"3335_CR55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","volume":"41","author":"P Vescovi","year":"2012","unstructured":"Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S (2012) Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 41:214\u201321","journal-title":"J Oral Pathol Med"},{"key":"3335_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.oraloncology.2011.08.010","volume":"48","author":"MA Matins","year":"2012","unstructured":"Matins MA, Martins MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA et al (2012) Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncol 48:79\u201384","journal-title":"Oral Oncol"},{"key":"3335_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","volume":"48","author":"M Mozzati","year":"2012","unstructured":"Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M (2012) Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 48:469\u201374","journal-title":"Oral Oncol"},{"key":"3335_CR58","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","volume":"12","author":"JJ Freiberger","year":"2012","unstructured":"Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW et al (2012) What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 12:1573\u201383","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3335-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3335-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T21:09:54Z","timestamp":1567285794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3335-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3335"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3335-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]}}}